GSK Plays Up Avandia As Diabetes “Engine” After DPP-4 Program Stalls
Executive Summary
GlaxoSmithKline does not believe development of its own dipeptidyl peptidase-4 inhibitor is integral to growing the firm's diabetes franchise
You may also be interested in...
GSK Hopes RECORD Sets Avandia Straight; Firm’s Diabetes Pipeline Bleak
If GlaxoSmithKline's Avandia is brought down by a potential cardiovascular safety signal, the firm will not have diabetes products graduating from its pipeline in the near term to fill the void
GSK Hopes RECORD Sets Avandia Straight; Firm’s Diabetes Pipeline Bleak
If GlaxoSmithKline's Avandia is brought down by a potential cardiovascular safety signal, the firm will not have diabetes products graduating from its pipeline in the near term to fill the void
Merck Ups Marketing Spend For Januvia And Gardasil As Competitors Stumble
Merck's decision to step up marketing spend for two of its new products, the DPP-4 inhibitor Januvia for diabetes and the human papilloma virus vaccine Gardasil,may reflect an effort to take advantage of delays in the launches of potential competitor products